Hyderabad: Publishing Clarification in the controversy of Covaxin prices in Brazil, Bharat Biotech said on Tuesday he followed a step-by-stage regulatory approval process for a period of eight months, but the company did not accept advance payments or providing vaccines to Brazilian health services (MOH) until now.
“In the case of the procurement of Covaxin by Moh Brazil, since the first meeting with Moh Brazil during November 2020, until June 29, 2021, a step-by-step approach has been followed towards the contract, and regulatory approval, for eight months.
The process – the authorization of emergency use (EUA) was received on 4.
June 29 June, Bharat Biotech has not received a down payment or provides any vaccine for Moh Brazil.
Bharat Biotech has followed the contract approach, approval and inventory.
In some countries around the world, where Covaxin is supplied with Success, “said a company statement.
Hyderabad-based companies clarify that Covaxin prices have been clearly set between USD 15 to USD 20 per dose for supply to the government outside India.
“Prices for Brazil have also been shown in USD 15 per dose.
Bharat Biotech has received advance payments from several other countries at the above price point, with inventory in the process, delay,” he added.
According to Bharat Biotech, Precisa Medicamentos is a partner in Brazil, providing assistance, guidance, and support with the submission of regulations, licenses, distributions, insurance, phase III clinical trial behavior, among others and Hyderabad-based vaccine makers follow similar partnership models in all countries, Where the vaccine is provided, because it does not have its own office in these countries.
The company also revealed that they were doing 5,000 subjects of phase III clinical trials in Brazil, which was recently approved by Anvisa.
The trial will be carried out by Albert Einstein Institute.
“Bharat Biotech and Precisa Medicamentos are conducting a clinical test of phase III subject 5000 in Brazil, which was recently approved by Anvisa.
The trial will be carried out by Albert Einstein Institute,” the statement rang.
However, according to the company, Covaxin has now received authorization of emergency use in 16 countries including, Brazil, India, the Philippines, Iran, Mexico, among other things and companies in the process of obtaining EUU in 50 other countries around the world.
“Bharat Biotech is discussing with WHO to get a list of emergency use for Covaxin.
This product has been exported to several countries, with additional requests for the supplies received,” said the company.
In the midst of the probe, allegations of irregularities against President Jair Bolsonaro, the Minister of Health Brazil has announced that the country will suspend the contract of USD 324 million to buy 20 million doses of Covaxin Bharat Biotech.
Overcoming a press conference on Tuesday with Health Minister Marcelo Queiroga, Head of the Federal Comtroller General (CGU) Wagner Rosario, said that the agency would investigate the vaccine purchase process.
“We suspend the agreement as a simple precautionary measure, because there are complaints that cannot be explained properly by the complainants, so we opened an investigation earlier last week,” Rosario said, as quoted by CNN Brazil.
“We have included a reinforced team for verification.
We hope to be very fast in this process, and we hope that no more than 10 days we have answered this analysis,”; He added.
Brazilian Health Minister Queiroga said his service would conduct an administrative investigation to verify all aspects of the problem being raised.
“As soon as we have more concrete data, we will communicate,” Queiroga said.
The contract for the acquisition of the Covaxin vaccine was signed by both parties in February to import 20 million vaccine doses by Bharat Biotech.
Bharat Biotech has denied receiving payments in advance, supplying vaccines to Brazil
